Fineline Cube

Follow:
14422 Articles
Innovent Secures 2nd NMPA Approval for Mazdutide – First Dual GLP‑1/GCGR Therapy for Type 2 Diabetes
CompanyDrug

Innovent Secures 2nd NMPA Approval for Mazdutide – First Dual GLP‑1/GCGR Therapy for Type 2 Diabetes

AusperBio Secures $63 Million Series B2 Financing to Propel AHB‑137 Development
CompanyDeals

AusperBio Secures $63 Million Series B2 Financing to Propel AHB‑137 Development

Pfizer and Arvinas Pass Commercial Rights of Vepdegestrant to Third Party
CompanyDeals

Pfizer and Arvinas Pass Commercial Rights of Vepdegestrant to Third Party

Guangdong Taienkang Secures NMPA Approval for Safinamide Generic
CompanyDrug

Guangdong Taienkang Secures NMPA Approval for Safinamide Generic

Hengrui Pharma Secures Breakthrough Therapy Designation for SHR‑1501 in China
CompanyDrug

Hengrui Pharma Secures Breakthrough Therapy Designation for SHR‑1501 in China

GE Healthcare Eyes Sale of China Unit Amid Revenue Decline
Others

GE Healthcare Eyes Sale of China Unit Amid Revenue Decline

Hengrui Pharma Secures NMPA Approval for Two Novel Immune‑Inflammatory Drugs
CompanyDrug

Hengrui Pharma Secures NMPA Approval for Two Novel Immune‑Inflammatory Drugs

GenSci Secures Exclusive Rights to ALK’s House Dust Mite Allergy Therapies in China
CompanyDeals

GenSci Secures Exclusive Rights to ALK’s House Dust Mite Allergy Therapies in China

Jiangsu Hengrui Secures Priority Review for Trastuzumab Rezetecan in HER2‑Positive Breast Cancer
CompanyDrug

Jiangsu Hengrui Secures Priority Review for Trastuzumab Rezetecan in HER2‑Positive Breast Cancer

Chongqing Genrix Secures NMPA Trial Approval for GR2301 IL‑15 Antibody in Vitiligo
CompanyDrug

Chongqing Genrix Secures NMPA Trial Approval for GR2301 IL‑15 Antibody in Vitiligo

Suzhou Zelgen Secures NMPA Approval for ZGGS34 TriTEs Targeting MUC17‑Positive Solid Tumors
CompanyDrug

Suzhou Zelgen Secures NMPA Approval for ZGGS34 TriTEs Targeting MUC17‑Positive Solid Tumors

Eli Lilly’s Orforglipron Outperforms Oral Semaglutide in ACHIEVE‑3 Phase 3 Trial
CompanyDrug

Eli Lilly’s Orforglipron Outperforms Oral Semaglutide in ACHIEVE‑3 Phase 3 Trial